Compared with Jiang's IDC cohort (n = 653),[23] we also observed that the known high‐frequency mutations of BC in our IDC cohort were almost consistent with that in Jiang's IDC cohort, including TP53 (IDC cohort in this study versus Jiang's IDC cohort, 34% versus 39.8%; p > 0.05) (Figure 1E, Table S2, Supporting Information). This evidence concerns the gene TP53 and breast cancer.